Regulatory Shock Overpriced; Valuations of Leading Pharmacies Hit Bottom

Overview

UBS Global Research published a report on China’s pharmaceutical retail industry addressing recent regulatory tightening concerns. On May 25, China’s National Medical Products Administration (NMPA) issued the 'Compliance Guidelines for Online Drug Sales.' Combined with mid-May media reports on tightened GLP-1 distribution channel regulations, this triggered a 7–10% stock price decline last week among offline pharmacies and healthcare e-commerce firms. Based on feedback from listed companies and channel checks, UBS believes the market overreacted—the actual impact is limited to online prescriptions for GLP-1 weight-loss indications, and leading listed companies are already largely compliant. The report reiterates Buy ratings on JD Health, Yifeng Pharmacy, and Dachanlin, noting valuations are at historical lows and the core thesis of rising online penetration remains unchanged.

Core views

Actual regulatory impact is limited, and the market overreacted. UBS’s core assessment rests on three points: First, the final NMPA guidelines contain no substantive changes versus the September 2025 draft, which the market had already priced in. Second, recent GLP-1 regulatory tightening targets only online prescriptions for weight-loss indications—not diabetes-related GLP-1 use or all prescription drugs broadly. Third, feedback from listed companies and channel verification shows minimal impact on online prescription processes and GLP-1 sales for listed pharmacy chains and e-commerce 1P businesses. Some smaller pharmacies using non-compliant third-party internet hospitals for e-prescriptions were affected, but leading enterprises’ operations already meet the new requirements. From a financial exposure perspective, listed pharmacy chains derive only ~1% of revenue from GLP-1, while e-commerce 1P businesses have low-to-mid single-digit revenue exposure—and even smaller gross profit contributions. Thus, even if GLP-1 sales face some headwinds, the impact on overall earnings is negligible. Few investors contacted by UBS have revised down earnings expectations. On valuation, the recent sector selloff reflects: (1) general underperformance in healthcare and internet sectors; (2) already elevated short interest in healthcare e-commerce prior to the event; (3) a 'sell first, ask questions later' reaction amid limited channel clarity; and (4) lack of near-term catalysts. JD Health now trades at 17x 2026E adjusted P/E—a historical low. Yifeng Pharmacy and Dachanlin trade at ~13x 2026E P/E, also at historical lows and at a discount to global pharmacy peers. Long-term trends remain intact. UBS believes that even with stricter regulation on online drug sales, the fundamental driver of rising online penetration in pharmaceutical retail remains unchanged, supported by three key factors: policy-driven prescription diversion, pharmaceutical companies expanding into retail channels, and evolving consumer behavior.

Analysis framework

UBS employs a three-stage analytical framework: 'Event Shock → Impact Quantification → Valuation Reassessment.' First, it identifies triggers: NMPA compliance guidelines, GLP-1 regulatory rumors, and NDRC meetings with pharmacy chains. Second, it differentiates actual impact between compliant and non-compliant players through company feedback and channel checks, quantifying revenue exposure. Finally, it assesses whether the market overreacted by analyzing sentiment (short interest, sector rotation) and historical valuation percentiles. For specific stock selection, UBS applies differentiated valuation methodologies: DCF for Yifeng Pharmacy and Dachanlin to reflect their asset-heavy retail models, and adjusted P/E for JD Health to account for its asset-light platform business model.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  DCF used for asset-heavy pharmacy chains

  UBS applies DCF to Yifeng Pharmacy and Dachanlin, discounting future free cash flows from store expansion to present value—suitable for evaluating offline retail models with clear capex and network growth plans.

• Valuation MethodPE/PEG valuation

  Adjusted P/E used for healthcare e-commerce platforms

  JD Health is valued using P/adjusted earnings, as platform profitability is heavily influenced by investment cycles and subsidy strategies; adjusted earnings better reflect sustainable core profitability.

• Industry/Thematic FrameworkSupply-demand framework

  Core tension in pharma retail lies in demand-side drivers (prescription diversion) and channel structure (online penetration)

  UBS focuses analysis on the triple demand drivers—'prescription diversion policy × online penetration × consumer behavior shift'—rather than just supply-side store count competition, explaining why short-term regulatory shocks don’t alter long-term trends.

• Event Arbitrage & Behavioral FinanceExpectation Gap / Expectation Management

  'Sell first, ask questions later' behavior led to overpricing

  UBS notes high pre-event short interest and opaque channel information caused markets to overreact without full data, creating an expectation gap and investment opportunity.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• JD Health (6618.HK)

  Leading healthcare e-commerce platform, directly benefits from rising online penetration, highly compliant with regulations

  Strengths

  Strong user mindshare, superior supply chain capabilities, operations already compliant with NMPA guidelines

  Comparison

  Trades at 17x 2026E adjusted P/E—historical low; asset-light model offers differentiated positioning vs. offline chains

  Risks

  Slower-than-expected医保 reimbursement progress, lower-than-expected consumer adoption of online pharmacy, failure in new business expansion, reduced support from JD Group

• Yifeng Pharmacy (603939.SS)

  Leading offline pharmacy chain; accelerating expansion amid industry consolidation to gain market share

  Strengths

  Accelerating store rollout, compliant operations, valuation at historical low

  Comparison

  Trades at ~13x 2026E P/E, below global pharmacy peers

  Risks

  Changes in医保 policy, classification management and pharmacist staffing requirements affecting expansion, intensified regional competition, online channel diversion

• Dachanlin (603233.SS)

  Leading offline pharmacy chain; benefits from industry consolidation under similar logic as Yifeng

  Strengths

  Accelerating store rollout, compliant operations, valuation at historical low

  Comparison

  Trades at ~13x 2026E P/E, below global pharmacy peers

  Risks

  Changes in医保 policy, classification management and pharmacist staffing requirements affecting expansion, intensified regional competition, online channel diversion

Key data

• JD Health 2026E Valuation17x P/adjusted earningsHistorical low
• Yifeng Pharmacy / Dachanlin 2026E Valuation~13x PEHistorical low, trading at discount to global peers
• Listed Pharmacy Chains’ GLP-1 Revenue Exposure~1%Impact extremely limited
• Healthcare E-commerce 1P GLP-1 Revenue ExposureLow-to-mid single digitsGross profit contribution even smaller
• Sector Decline Last Week7–10%Offline pharmacies and healthcare e-commerce

Impact & implications

The report argues that the current regulatory environment has limited impact on compliant, listed market leaders, and the market selloff has created a valuation recovery opportunity. JD Health, with strong user mindshare and supply chain capabilities, stands to benefit further from rising online penetration. Yifeng Pharmacy and Dachanlin, accelerating store expansion amid industry-wide closures, may deliver earnings upside and valuation recovery. However, if regulators strictly enforce 'online prescriptions only for follow-up visits' (requiring doctors to verify offline prescriptions or medical records before issuing e-prescriptions), this could pose a new downside risk to earnings—though UBS sees no signs of such enforcement in the near term.

Risks

• Changes in医保 policy—especially reimbursement scope and pharmacy reimbursement pricing—could significantly affect pharmacy foot traffic and margins.
• Classification management and pharmacist staffing requirements directly impact store expansion plans and operating costs.
• Pharmacy violations could lead to loss of医保定点资格 or revocation of business licenses.
• Accelerated industry consolidation and rise of regional champions may hinder cross-regional expansion, intensifying direct competition among national leaders.
• E-commerce drug prices are typically lower than offline; shifting patient habits could drive offline traffic online.
• Strict enforcement of 'online prescriptions only for follow-up visits' could become a new earnings downside risk.

What to watch

• NMPA’s enforcement intensity against illegal activities and progress in integrating online/offline regulation
• Third-party platform disclosure requirements and regulatory strengthening
• Progress on医保 reimbursement, especially speed of basic医保 inclusion
• Changes in consumer acceptance of online pharmaceutical retail and healthcare services
• JD Health’s new business expansion progress and level of support from JD Group